Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Neutralase proceeds to phase III trials

Oct. 3, 1997

Cor Therapeutics submits NDA amendment for Integrilin to FDA

Oct. 2, 1997

Clinical results presented for Knoll's PEG-hirudin

Sep. 30, 1997

SKB reports new antiplatelet agents

Sep. 29, 1997

Astra describes prodrugs of thrombin inhibitors

Sep. 26, 1997

rNAPc2 completes phase Ia testing with positive results

Sep. 25, 1997

Lilly presents structurally novel thrombin inhibitors

Sep. 24, 1997

First approvals for Lovenox/Clexane in unstable angina/MI

Sep. 22, 1997

TP-9201 as adjunct to thrombolysis in stroke

Sep. 22, 1997

Lilly describes lead for orally active thrombin inhibitors

Sep. 19, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...